Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. Iatrogenic hypoglycaemia is typically the result of the interplay of insulin excess and compromised glucose counterregulation in Type I (insulin-dependent) diabetes mellitus. Insulin concentrations do not decrease and glucagon and epinephrine concentrations do not increase normally as glucose concentrations decrease. The concept of hypoglycaemia-associated autonomic failure (HAAF) in Type I diabetes posits that recent antecedent iatrogenic hypoglycaemia causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of an absent glucagon response) and hypoglycaemia unawareness (by reducing the autonomic and the resulting neurogenic symptom responses). Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglycaemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients. The mediator and mechanism of HAAF are not known but are under active investigation. The glucagon response to hypoglycaemia is also reduced in patients approaching the insulin deficient end of the spectrum of Type II (non-insulin-dependent) diabetes mellitus, and glycaemic thresholds for autonomic (including epinephrine) and symptomatic responses to hypoglycaemia are shifted to lower plasma glucose concentrations after hypoglycaemia in Type II diabetes. Thus, patients with advanced Type II diabetes are also at risk for HAAF. While it is possible to minimise the risk of hypoglycaemia by reducing risks -- including a 2 to 3 week period of scrupulous avoidance of hypoglycaemia in patients with hypoglycaemia unawareness -- methods that provide glucose-regulated insulin replacement or secretion are needed to eliminate hypoglycaemia and maintain euglycaemia over a lifetime of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84 -86).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12,16,84,85).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (e.g.nateglinide or repaglinide).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, deficiency of the secretory response of glucagon to hypoglycemia is an early acquired abnormality of counterregulation.The catecholamine response compensates for several years but declines with time (1).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Enough insulin, or any effective drug, to lower plasma glucose concentrations to or below the normal range would eliminate the symptoms of hyperglycaemia, prevent the acute hyperglycaemic complications (ketoacidosis, hyperosmolar syndrome), almost assuredly prevent the long-term microvascular complications [1, 2] and…”
BackgroundKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Finally, we and others have begun to study the mechanisms of the normal glucagon response to hypoglycaemia with the aim of gaining insight into the mechanism of the absence of the glucagon response in Type I diabetes [22], a critical component of defective glucose counterregulation and HAAF.”
BackgroundMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citation&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citation
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“Hypoglycemia is the leading limiting factor in the glycemic management of type 1 and insulin-treated type 2 diabetes (289).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“Hypoglycemia is the leading limiting factor in the glycemic management of type 1 and insulin-treated type 2 diabetes (223).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
“as normal a glycaemic profile as possible without unacceptable weight gain or hypoglycaemia [73].”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
“Hypoglycemia, especially in insulin-treated patients, is the leading limiting factor in the glycemic management of type 1 and type 2 diabetes (165).”
BackgroundStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
“Hypoglycemia is the leading limiting factor in the glycemic management of type 1 and insulin-treated type 2 diabetes (146).”
Standards of Medical Care in Diabetes–2006
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s4 · Cited by 1,885
“Preventing hypoglycemia Hypoglycemia, especially in insulintreated patients, is the leading limiting factor in the glycemic management of type 1 and type 2 diabetes (93).”
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Standards of Medical Care in Diabetes 2014
(2014) · Majmaah Journal of Health Sciences · doi:10.12816/0004790 · Cited by 1,465
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
“Preventing hypoglycemia Hypoglycemia, especially in insulintreated patients, is the leading limiting factor in the glycemic management of type 1 and type 2 diabetes (117).”
BackgroundCare of Children and Adolescents With Type 1 Diabetes
Silverstein, J., Klingensmith, G., Copeland, K., Plotnick, L., Kaufman, F., Laffel, L., Deeb, L., Grey, M., Anderson, B., Holzmeister, L. A., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.186 · Cited by 1,312
“Hypoglycemia The desire to avoid hypoglycemia is one of the major barriers to achieving nearnormal glycemic control (113).”
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Self-citationManagement of diabetes and hyperglycemia in hospitals.
Clement, S., Braithwaite, S. S., Magee, M. F., Ahmann, A., Smith, E. P., Schafer, R. G., Hirsch, I. B., & on behalf of the Diabetes in Hospitals Writing Committee (2004) · Diabetes Care · doi:10.2337/diacare.27.2.553 · Cited by 1,266
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
“Preventing hypoglycemia Hypoglycemia, especially in insulintreated patients, is the leading limiting factor in the glycemic management of type 1 and type 2 diabetes (86).”
BackgroundCryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
“Pending the prevention and cure of diabetes, people with diabetes need treatment methods that provide glucoseregulated insulin replacement or secretion if they are to consistently achieve and maintain euglycemia safely (1).”
BackgroundInfluentialSelf-citationThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Increased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539
“CONCLUSIONSdHypoglycemia is the most common significant and treatmentlimiting adverse effect in patients with diabetes (9,10).”
BackgroundEffect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
Battelino, T., Phillip, M., Bratina, N., Nimri, R., Oskarsson, P., & Bolinder, J. (2011) · Diabetes Care · doi:10.2337/dc10-1989 · Cited by 490
“Intensive insulin treatment and lower HbA1c increase exposure to hypoglycemia (3,4).”
BackgroundHypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
“The effects of type 2 diabetes on the responses to hypoglycemia Counterregulatory responses to hypoglycemia have been investigated less systematically in type 2 than in type 1 diabetes (1,27,28).”
BackgroundInfluentialMiller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
“Loss of warning signs (hypoglycaemia unawareness) and severe episodes become more prevalent as glycaemia control improves to the point that glucose levels are at normal or near normal levels. Indeed, hypoglycaemia has been identified as the limiting factor that prevents patients with diabetes from achieving excellent…”
BackgroundPhysiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes
Quesada, I., Tudurí, E., Ripoll, C., & Nadal, Á. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0290 · Cited by 412
“In this regard, iatrogenic hypoglycaemia is a situation that implies insulin excess and compromised glucose counter-regulation, and it is responsible for a major complication in diabetes treatment, increasing the morbidity and mortality of this disease (Cryer 2002).”
BackgroundDiverse causes of hypoglycemia-associated autonomic failure in diabetes.
Cryer, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031354 · Cited by 411
Self-citation(Pre)diabetes, brain aging, and cognition
S. Roriz-Filho, J., Sá-Roriz, T. M., Rosset, I., Camozzato, A. L., Santos, A. C., Chaves, M. L. F., Moriguti, J. C., & Roriz-Cruz, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.003 · Cited by 386
“In thepresenceof hypoglycemia, several responses occurwithin the brain, including activation of the central sympathetic nervous system, promoting physiological changes manifested as autonomic symptoms such as sweating, tremor, a pounding heart, hunger, and anxiety [127,128].”
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
Reduced Hypoglycemia Risk With Insulin Glargine
Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., & Salzman, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.950 · Cited by 371
“Furthermore, there is a growing awareness of the previously underrecognized risk of hypoglycemia, particularly nocturnal as well as severe hypoglycemia (5), and a pressing need for the prevention of hypoglycemic episodes in these patients (6,7).”
BackgroundPedersen‐Bjergaard, U., Pramming, S., Heller, S. R., Wallace, T. M., Rasmussen, Å. K., Jørgensen, H. V., Matthews, D. R., Hougaard, P., & Thorsteinsson, B. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.482 · Cited by 371
“Despite continuous efforts to improve treatment of type 1 diabetes, severe hypoglycaemia remains a major limiting factor for achievement of optimal glycaemic control [1,2].”
BackgroundGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366
Hermansen, K., Fontaine, P., Kukolja, K. K., Peterkova, V., Leth, G., & Gall, M.-A. (2004) · Diabetologia · doi:10.1007/s00125-004-1365-z · Cited by 365
Riddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. D. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346
“org because the negative physiological, social and psychological consequences of these episodes challenge the willingness of physicians and patients to increase the dose [5].”
BackgroundAssessment and monitoring of glycemic control in children and adolescents with diabetes
Rewers, M., Pihoker, C., Donaghue, K., Hanas, R., Swift, P., & Klingensmith, G. J. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00582.x · Cited by 342
Vascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
“Additionally, the risk, consequences, and fear of hypoglycemia remain a significant limiting factor in intensifying insulin therapy and optimizing glycemic control (9).”
Evaluation of a New Measure of Blood Glucose Variability in Diabetes
Kovatchev, B. P., Otto, E., Cox, D., Gonder-Frederick, L., & Clarke, W. (2006) · Diabetes Care · doi:10.2337/dc06-1085 · Cited by 333
Garber, A. J., King, A. B., Prato, S. D., Sreenan, S., Balci, M. K., Muñoz-Torres, M., Rosenstock, J., Endahl, L. A., Francisco, A. M. O., & Hollander, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60205-0 · Cited by 325
Assessment and monitoring of glycemic control in children and adolescents with diabetes
Rewers, M. J., Pillay, K., de Beaufort, C., Craig, M. E., Hanas, R., Acerini, C. L., & Maahs, D. M. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12190 · Cited by 316
Closed-loop insulin delivery—the path to physiological glucose control
Steil, G. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.08.011 · Cited by 313
Bergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307
Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 305
“Tight glycaemic control is known to increase the risk of hypoglycaemia, representing a major barrier to sustained good glycaemic control with insulin therapy (9, 12).”
BackgroundHypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes
Bremer, J. P., Jauch-Chara, K., Hallschmid, M., Schmid, S., & Schultes, B. (2009) · Diabetes Care · doi:10.2337/dc09-0114 · Cited by 298
“Given that the risk of hypoglycemia increases with the efficacy of glycemic control as reflected by low A1C levels (1,3), our results strongly support the view that glycemic targets for patients should be defined on an individual basis, thus taking into account factors such as age and probably also disease duration.”
BackgroundBarriers to self‐management of diabetes
Ahola, A. J., & Groop, P. ‐. (2013) · Diabetic Medicine · doi:10.1111/dme.12105 · Cited by 285
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 286
Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
Siebenhofer, A., Plank, J., Berghold, A., Jeitler, K., Horvath, K., Narath, M., Gfrerer, R., & Pieber, T. R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003287.pub4 · Cited by 264
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
KATP channels and islet hormone secretion: new insights and controversies
Ashcroft, F. M., & Rorsman, P. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.166 · Cited by 272
Glucose or Insulin, but not Zinc Ions, Inhibit Glucagon Secretion From Mouse Pancreatic α-Cells
Ravier, M. A., & Rutter, G. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1789 · Cited by 264
De Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257
“This would explain why impaired counterregulation is often seen in diabetic patients (Cryer, 2002).”
BackgroundInfluentialGlucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes
Kovatchev, B., & Cobelli, C. (2016) · Diabetes Care · doi:10.2337/dc15-2035 · Cited by 255
“Consequently, hypoglycemia has been implicated as the primary barrier to tight control (7,8).”
BackgroundMacDonald, P. E., Marinis, Y. Z. D., Ramracheya, R., Salehi, A., Ma, X., Johnson, P. R. V., Cox, R., Eliasson, L., & Rorsman, P. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050143 · Cited by 246
“Diabetes mellitus is associated with defects of glucagon secretion that exacerbate the consequences of impaired insulin secretion [2–4].”
BackgroundChico, A., Vidal-Ríos, P., Subirà, M., & Novials, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1153 · Cited by 235
Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits
Ginde, A. A., Blanc, P. G., Lieberman, R. M., & Camargo, C. A. (2008) · BMC Endocrine Disorders · doi:10.1186/1472-6823-8-4 · Cited by 234
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
“S evere hypoglycemia is an acute complication of insulin therapy that can lead to seizures, coma, and death (1) and creates a barrier to optimal glycemic control in diabetes management (2).”
BackgroundAccuracy of the 5-Day FreeStyle Navigator Continuous Glucose Monitoring System
Weinstein, R. L., Schwartz, S. L., Brazg, R. L., Bugler, J. R., Peyser, T. A., & McGarraugh, G. V. (2007) · Diabetes Care · doi:10.2337/dc06-1602 · Cited by 228
“Real-time continuous glucose monitoring devices can alert patients to high or low glucose levels that might be undetected by episodic capillary blood measurements, making possible tight glycemic control without a concomitant increase in the incidence or fear of hypoglycemia (4,5).”
BackgroundTanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Zhang, Q., Ramracheya, R., Lahmann, C., Tarasov, A., Bengtsson, M., Braha, O., Braun, M., Brereton, M., Collins, S., Galvanovskis, J., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.014 · Cited by 225
“The glucagon secretory defects include oversecretion at high glucose (when it is not needed) and inadequate release at low glucose (when it is needed) (Cryer, 2002; Unger and Cherrington, 2012).”
BackgroundHypoglycaemia and cognitive function
Warren, R. E., & Frier, B. M. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00421.x · Cited by 218
Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells
Vieira, E., Salehi, A., & Gylfe, E. (2007) · Diabetologia · doi:10.1007/s00125-006-0511-1 · Cited by 218
“This glucose counterregulation is also impaired in diabetes, and hypoglycaemia is a significant cause of death in insulin-treated patients [7].”
BackgroundHaidar, A., Legault, L., Messier, V., Mitre, T. M., Leroux, C., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70226-8 · Cited by 214
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s009 · Cited by 205
Kovatchev, B. P., Clarke, W. L., Breton, M., Brayman, K., & McCall, A. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.849 · Cited by 201
Glycogen: The forgotten cerebral energy store
Gruetter, R. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10785 · Cited by 194
Li, Q., Liao, J., Chen, W., Zhang, K., Li, H., Ma, F., Zhang, H., Han, Q., Guo, J., Li, Y., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.05.024 · Cited by 191
Assessment and management of hypoglycemia in children and adolescents with diabetes
Clarke, W., Jones, T., Rewers, A., Dunger, D., & Klingensmith, G. J. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00405.x · Cited by 189
Gerstein, H. C., Riddle, M. C., Kendall, D. M., Cohen, R. M., Goland, R., Feinglos, M. N., Kirk, J. K., Hamilton, B. P., Ismail-Beigi, F., & Feeney, P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.004 · Cited by 186
Sleep-Related Hypoglycemia-Associated Autonomic Failure in Type 1 Diabetes
Banarer, S., & Cryer, P. E. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1195 · Cited by 187
“The reduced cortisol response to hypoglycemia during sleep in diabetic subjects is relevant to the suggestion that it is the cortisol response to prior hypoglycemia that mediates reduced autonomic (including epinephrine) and symptomatic responses to subsequent hypoglycemia (25– 26), that is, that cortisol is the media…”
InfluentialSelf-citationIslet Transplantation for Brittle Type 1 Diabetes: The UIC Protocol
Gangemi, A., Salehi, P., Hatipoglu, B., Martellotto, J., Barbaro, B., Kuechle, J. B., Qi, M., Wang, Y., Pallan, P., Owens, C., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02234.x · Cited by 184
Ma, K., Yuen, J. M., Shah, N. C., Walsh, J. T., Glucksberg, M. R., & Van Duyne, R. P. (2011) · Analytical Chemistry · doi:10.1021/ac202343e · Cited by 184
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Wright, L. A.-C., & Hirsch, I. B. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0029 · Cited by 178
“Hypoglycemia is the major barrier in patients with DM and the limiting factor to achieve euglycemia.(97) Studies have linked hypoglycemia with excessive morbidity and mortality.”
BackgroundSarkar, U., Karter, A. J., Liu, J. Y., Moffet, H. H., Adler, N. E., & Schillinger, D. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1389-7 · Cited by 173
Haidar, A., Legault, L., Dallaire, M., Alkhateeb, A., Coriati, A., Messier, V., Cheng, P., Millette, M., Boulet, B., & Rabasa-Lhoret, R. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121265 · Cited by 167
“Hypoglycemia remains the major barrier to the intensification of insulin therapy.(4) Intensive insulin therapy and lower levels of glycated hemoglobin are unfortunately associated with an increased risk of hypoglycemia.”
BackgroundMartyn-Nemeth, P., Schwarz Farabi, S., Mihailescu, D., Nemeth, J., & Quinn, L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.09.003 · Cited by 165
“Hypoglycemia remains the major limiting factor in achieving optimal blood glucose control in persons with type 1 diabetes (T1DM) (Cryer, 2002).”
BackgroundMelatonin and Pancreatic Islets: Interrelationships between Melatonin, Insulin and Glucagon
Peschke, E., Bähr, I., & Mühlbauer, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14046981 · Cited by 165
“characteristic in diabetes [200,201].”
Pieber, T. R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Kaspers, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12494 · Cited by 166
Bergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700234 · Cited by 166
Neuroendocrine responses to hypoglycemia
Tesfaye, N., & Seaquist, E. R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05820.x · Cited by 164
Barendse, S., Singh, H., Frier, B. M., & Speight, J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03416.x · Cited by 161
Localized in vivo13C NMR spectroscopy of the brain
Gruetter, R., Adriany, G., Choi, I., Henry, P., Lei, H., & Öz, G. (2003) · NMR in Biomedicine · doi:10.1002/nbm.841 · Cited by 161
“Since concentration changes are induced by a mismatch in catabolic and anabolic flux of glycogen, it is, however, reasonable to assume that elevated brain glycogen concentrations, such as the ones seen after hypoglycemia in the rat, may take days to weeks to be normalized, which incidentally is consistent with the tim…”
BackgroundBartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159
Yeoh, E., Choudhary, P., Nwokolo, M., Ayis, S., & Amiel, S. A. (2015) · Diabetes Care · doi:10.2337/dc15-0102 · Cited by 154
“Hypoglycemia remains the major limiting factor toward achieving good glycemic control (1).”
Backgroundδ‐cells and β‐cells are electrically coupled and regulate α‐cell activity via somatostatin
Briant, L. J. B., Reinbothe, T. M., Spiliotis, I., Miranda, C., Rodriguez, B., & Rorsman, P. (2018) · The Journal of Physiology · doi:10.1113/jp274581 · Cited by 155
“The abnormalities in glucagon secretion in T2DM include both loss of adequate suppression under hyperglycaemic conditions and insufficient release during episodes of hypoglycaemia (Cryer, 2002, 2008; Cryer et al. 2003; Dunning et al. 2005; D’Alessio, 2011; Unger & Cherrington, 2012).”
BackgroundWright, A. D., Cull, C. A., Macleod, K. M., & Holman, R. R. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.08.010 · Cited by 153
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
Vergari, E., Knudsen, J. G., Ramracheya, R., Salehi, A., Zhang, Q., Adam, J., Asterholm, I. W., Benrick, A., Briant, L. J. B., Chibalina, M. V., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08193-8 · Cited by 152
Assessment and management of hypoglycemia in children and adolescents with diabetes
Ly, T. T., Maahs, D. M., Rewers, A., Dunger, D., Oduwole, A., & Jones, T. W. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12174 · Cited by 151
Schopman, J. E., Geddes, J., & Frier, B. M. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.013 · Cited by 150
“Hypoglycaemia is a major limitation to achieving strict glycaemic control in Type 1 diabetes [1] and the acquired syndrome of impaired awareness of hypoglycaemia (IAH) is a major risk factor for severe events.”
Mullins, P. R., Sharplin, P., Yki‐Järvinen, H., Riddle, M. C., & Häring, H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.020 · Cited by 156
Kealy, J., Murray, C., Griffin, É. W., López-Rodríguez, A. B., Healy, D., Tortorelli, L. S., Lowry, J. P., Watne, L. O., & Cunningham, C. M. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2876-19.2020 · Cited by 168
“Iatrogenic hypoglycemia is common in patients using insulin for diabetes (Cryer, 2002) and is a major cause of emergency department admissions and adverse CNS effects in older patients (Shehab et al., 2016).”
BackgroundAvoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Ahren, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33934 · Cited by 148
Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
Robertson, K. J., Schoenle, E., Gucev, Z., Mordhorst, L., Gall, M. ‐., & Ludvigsson, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02024.x · Cited by 149
Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values
Garg, S., & Jovanovic, L. (2006) · Diabetes Care · doi:10.2337/dc06-1361 · Cited by 148
“Lowering of A1C is desirable if it can be accomplished without increasing the incidence of hypoglycemia (18,20).”
BackgroundHypoglycemia as a barrier to glycemic control
Davis, S. N., & Alonso, M. D. (2004) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(03)00058-8 · Cited by 155
“However, the epinephrine secretory response to hypoglycemia decreases after frequent hypoglycemic episodes (Cryer, 2002), which, under intensive therapeutic conditions, results in a 25-fold increase in the risk of severe hypoglycemia (White et al.”
BackgroundInfluentialThe α-cell in diabetes mellitus
Gromada, J., Chabosseau, P., & Rutter, G. A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0097-y · Cited by 143
Bergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
“Researchers completed such a study in individuals with T2D at high risk for CVD using a prandial versus basal insulin approach.”
BackgroundInfluentialMarrett, E., Radican, L., Davies, M. J., & Zhang, Q. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-251 · Cited by 137
“This treatment limitation, induced by some glucose-lowering medications, may be a major barrier to successful diabetes care [4, 5 ].”
BackgroundRamracheya, R., Ward, C., Shigeto, M., Walker, J. N., Amisten, S., Zhang, Q., Johnson, P. R., Rorsman, P., & Braun, M. (2010) · Diabetes · doi:10.2337/db09-1505 · Cited by 136
“Diabetes 59:2198–2208, 2010 Glucagon is the principal hyperglycemic hormone (1,2).”
Assessment and management of hypoglycemia in children and adolescents with diabetes
Clarke, W., Jones, T., Rewers, A., Dunger, D., & Klingensmith, G. J. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00583.x · Cited by 135
Metadata
- Authors
- Cryer, P.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, P.
- Venue
- Diabetologia
- Published
- 2002-06
- Volume
- 45
- Issue
- 7
- Pages
- 937-948
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2124282046
- Semantic Scholar
- ebdcc733bdd208ee1005932d38511abefb8034d6
- Cited by
- 794
- References
- 58
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 39 · 2017: 49 · 2016: 32 · 2015: 60 · 2014: 65 · 2013: 66 · 2012: 53
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020579-35)
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, R37-DK27085, T32 DK07120, T32DK007120)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, hypoglycemia unawareness, glucose counterregulation, insulin excess, epinephrine response, glucagon response, type 1 diabetes, type 2 diabetes, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Epinephrine, Glucagon, Humans, Hypoglycemia, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.